| Top Adding |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Legal > National State Local > Non-compete Contract Basics in Michigan |
|
Top Adding - Non-compete Contract Basics in Michigan
In Michigan, as in other states, the broader the no-compete clause, the less enforcea According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ble the no-compete clause will be. On the other hand, the more an employee has acces ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in to confidential information, trade secrets and the payment of additional compensati lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. n for a non-compete clause increases the likelihood of no-compete enforcement in cour here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe . To enforce a non-compete, an employer must have a legitimate business interest to d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro rotect. In addition, an employer’s reasonable competitive business interest must als ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc o be more than merely competition. These include protection of trade secrets, propri easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi tary information, and competitive position. Taking insider information by an employee nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically which would lead to an "unfair advantage" to the employee, is key. Unfair advantage and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ however, is more than just competition. A non-compete is subject to attack when the ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi mployee does not use the trade secrets but only his general knowledge or things he ha ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a s learned from experience. Another issue in many of these cases is solicitation of c dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod stomers. Oftentimes, employers will include a contract clause that prohibits an empl cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin yee from providing services or contacting customers of the employer. Courts are more tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen likely to enforce non-solicitation clauses than no-contact or no-service clauses. Th t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel s is because courts view these clauses to be anti-trust violations and otherwise anti ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust -competitive since it takes the choice away from the consumer. At best, the distinct y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products on between solicitation and non-solicitation is somewhat artificial and subjective. . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ustomer letters and phone calls are obviously direct solicitation. Newspaper adverti elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ements typically are not considered solicitation and leave the customer choice intact tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:RSS Feed Can Make Your Business Famous Auto Insurance For Your Teenager
|